Infliximab effectiveness in COVID-19 patients

Phase 2

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20201229049873N1
• Lead Sponsor: Shahre-kord University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients with Covid-19 with acute respiratory symptoms between the ages of 18 and 60 who test positive for the SARS-CoV-19 virus by RT-PCR or by CT scan. Lung scan (subpleural lung involvement, bilateral circumference, and more than one area).
Saturated oxygen is below 88%
Respiratory rate more than 24 times per minute
high CRP and D-dimer level, also ferritin above 1000
Lymphopenia with a count of less than 1100

Exclusion Criteria

Patients who have a positive test for PPD, HCV, HBS
Patients Have a history of neurodegenerative diseases such as multiple sclerosis
Patients with heart failure, hypertension, and infections other than Covid 19 infection.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in paraclinical outcomes. Timepoint: At the beginning of the study (before the intervention) and 7 and 14 days after the start of treatment. Method of measurement: Clinical and laboratory testing.;Blood oxygen levels. Timepoint: At the beginning of the study (before the intervention) and 7 and 14 days after the start of treatment. Method of measurement: Pulse oximeter.;Duration of hospitalization. Timepoint: From the beginning of the study. Method of measurement: Clinical and vital signs.